Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression

Figure 3 Central area movement distance and total movement distance of open-field test mice after treatment. A: Moving distance of central area in depression groups; B: Moving distance of central area in chronic restraint stress, dextran sodium sulfate and compound model groups; C: Total moving distance in depression groups; D: Total moving distance in chronic restraint stress, dextran sodium sulfate and compound model groups. ^aP < 0.01 vs control group; ^bP < 0.01 vs chronic restraint stress group; ^cP < 0.01 vs chronic restraint stress + dextran sodium sulfate group; ^dP < 0.01 vs mesalazine group; ^fP < 0.05 vs control group; ^gP < 0.05 vs chronic restraint stress group; ^hP < 0.05 vs chronic restraint stress + dextran sodium sulfate group; ⁱP < 0.05 vs mesalazine group. CUMS: Chronic restraint stress; DSS: Dextran sodium sulfate; LD: Low-dose Wuling powder; MD: Medium-dose Wuling powder; HD: High-dose Wuling powder; FLU: Fluoxetine; MS: Mesalazine.